Resources
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- Biostar Raises $3.6 Million
- ChinaBio Today submits: Biostar Pharmaceuticals, Inc. (BSPM.OB) has completed a private placement that raised $3.6 million in new capital. Biostar will use the proceeds to complete its new raw materials processing facility. By taking its raw material production in house, Biostar will lower costs and ensure its product quality....
- External links 2009-11-08
- Bayer Launches New Anti-Clotting Drug in China
- ChinaBio Today submits: Bayer Healthcare (BAYRY.PK) has launched its new anti-clotting drug Xarelto rivaroxaban in China following SFDA approval. As Liam Condon, Managing Director of Bayer HealthCare China said at last week’s ChinaBio® Partnering Forum, the fact that Xarelto was approved in China before the US shows Bayer’s commitment...
- External links 2009-07-05
- Chemspec IPO Opens Strong
- ChinaBio Today submits: During the past week, two China pharma-related companies successfully completed their IPOs, ending a long drought of new offerings. Guilin Sanjin Pharmaceutical Co, a traditional Chinese medicine company, will make its debut on the Shenzhen exchange. On the New York Stock Exchange, chemical company Chemspec CPC,...
- External links 2009-07-05
- China Pharma Wins OK for Generic Cholesterol Drug Trials
- ChinaBio Today submits: China Pharma Holdings (CPHI.OB) obtained approval from the SFDA to begin Phase I and Phase II clinical trials of Rosuvastatin, a generic version of the cholesterol-lowering statin drug Crestor. The trials will test the compound for efficacy. China Pharma will move to begin the trials immediately...
- External links 2009-06-23
- Sinovac Gets Significant Order for H1N1 Flu Vaccine
- ChinaBio Today submits: Sinovac Biotech (NYSE Amex: SVA) received the first order for its influenza A (H1N1) vaccine from the Beijing government. The initial order, consisting of 4 million doses, will be administered to 2 million high risk people. Following delivery of the first order at the end of...
- External links 2009-06-22
- China Medical Technologies See Revenues Climb in '08
- ChinaBio Today submits: China Medical Technologies (NSDQ: CMED), a company that is prospering by focusing on in vitro diagnostic devices, reported preliminary financial data from its fiscal 2008 year, which ended March 31, 2009. The company said revenue increased 51% to $121 million, while net income jumped 80% to...
- External links 2009-06-21
- Pfizer: Looking to Do Deals in Emerging Markets
- ChinaBio Today submits: Pfizer Inc (NYSE: PFE) will use acquisitions and partnerships in an effort to become the number one drug seller in emerging markets such as China. Currently, Pfizer occupies the number three position. The emerging markets sector is worth $80 billion currently, and is expected to grow...
- External links 2009-06-21
- Tianyin Projects Positive 2009
- ChinaBio Today submits: Tianyin Pharmaceutical Co., TPI, whose fiscal year ends in two weeks on June 30, announced it expects to report revenues of $42 million and net income of $7.5 million in its 2009 fiscal year. Both numbers reflect an increase of 25% over year earlier results.Tianyin also...
- External links 2009-06-18
- China Aoxing Completes Codeine Product Trial
- ChinaBio Today submits: China Aoxing Pharmaceutical Company (CAXG.OB) reported that it has completed the registration trial of Codeine Phosphate, an oral solution that treats acute moderate to severe cough. The company plans to announce top-line results from the trial by the end of Q3 of 2009. China Aoxing said...
- External links 2009-06-19
- Vital Images to Offer Scanning Software to Hospitals in China Through Chindex
- ChinaBio Today submits: Vital Images (NSDQ: VTAL) will distribute its visualization software for CT and MR scans in China through Chindex International (NSDQ: CHDX). Vital Images has already obtained SFDA approval for its product, which Chindex will market to hospitals throughout China. Specific financial terms of the arrangement were...
- External links 2009-06-18
- Lilly Offers Free Compound Testing in Collaboration with Lab Researchers
- ChinaBio Today submits: Eli Lilly (NYSE: LLY) has taken another step in implementing its transformation from a fully integrated big pharma to a partnership arrangement, which it now calls a Fully Integrated Pharmaceutical Network FIPNet. The goal is to foster open collaboration between Lilly and global laboratory researchers.Lilly calls...
- External links 2009-06-17
- NeoStem Makes Good on China Medical Tourism Initiative with Stem Cell Deal
- ChinaBio Today submits: NeoStem, Inc. NBS, a company built on collection and storage of adult stem cells, signed an exclusive 10-year agreement with Enhance BioMedical Holdings Limited of Shanghai. Using NeoStem developed techniques, Enhance will build a stem cell collection and treatment network. The facilities are targeted for Shanghai,...
- External links 2009-06-15
- China Biopharma Companies Seize Opportunities in U.S. Real Estate
- ChinaBio Today submits: As China biopharma continues to evolve, the once dominant model of Western companies seeking opportunities in Asia, a uni-directional relationship, shows signs of giving way to increased bi-directional cooperation between West and East. In the last eighteen months, we have seen two large transactions in which...
- External links 2009-06-12
- Commonwealth Biotechnologies Expands Presence in Peptides
- ChinaBio Today submits: Commonwealth Biotechnologies, Inc. (NSDQ: CBTE) has agreed to acquire privately owned GL Biochem Shanghai Ltd., a manufacturer of peptide products and reagents. In 2008, GL Biochem produced $13 million of revenue and $2 million of net income, representing a compound annual growth rate of 40%. In...
- External links 2009-06-11
- Pfizer, Fudan University Partner to Offer New Graduate Program in China
- ChinaBio Today submits: Pfizer (NYSE: PFE) and Fudan University, located in Shanghai, are working together to create a graduate program in Clinical Data Management and Statistical Programming. Starting in September, the University will offer a three-year Masters Degree program, the first such program in China. The program will combine...
- External links 2009-07-31
- NeoStem Raises an Additional $4 Million
- ChinaBio Today submits: NeoStem, Inc. NBS has raised another $4 million from institutional and private investors. The terms of the funding were the same as those for the company’s previous fund raising, an $11 million private placement in April involving three Asia-based investors. Also, affiliates of Suzhou...
- External links 2009-07-05
- WuXi: One of China's Top 10 Outsourcing Companies
- ChinaBio Today submits: WuXi PharmaTech WX was named one of the Top Ten Leading Outsourcing Enterprises in China, a list selected by China’s Ministry of Commerce. The ministry announced the composition of the list at the Second Annual China International Service Outsourcing Cooperation Conference, held in Nanjing on June...
- External links 2009-07-05
- Lotus Receives Diabetes Drug Patent
- ChinaBio Today submits: Lotus Pharmaceuticals (LTUS.OB) has received a patent pending notice from China’s Intellectual Property Office for Gliclazide-Controlled Release Tablets, a controlled release form of the hypoglycemic drug gliclazide that is aimed at type 2 diabetes. Lotus filed for the patent in 2008. According to Lotus, the SFDA...
- External links 2009-07-31
- Pfizer Underwrites Basic Research at Shanghai Institutes
- ChinaBio Today submits: Pfizer (NYSE: PFE) has teamed up with the Shanghai Institutes for Biological Sciences (SIBS) to do basic research. The biggest of pharmas will underwrite $500,000 of health-related basic research projects at SIBS for each of the next three years. Pfizer and SIBS will select the research...
- External links 2009-07-30
- J&J Wins Approval to Market MDS Drug Without China Trials
- ChinaBio Today submits: Xian-Janssen, a division of Johnson & Johnson (NYSE: JNJ) has launched a new drug in China. Dacogen decitabine, a novel treatment for myelodysplastic syndrome, received SFDA approval through the Green Channel, an expedited approval process that the SFDA introduced in January 2009. In Dacogen’s case, the...
- External links 2009-07-25
- << Previous
- page 1 of 13
- Next >>
Refining Tags
- China (216 results)
- Biotech (39 results)
- Seeking Alpha (34 results)
- China Sky One Medical Inc. (24 results)
- Finance (23 results)
- Sinovac Biotech Ltd. (20 results)
- Healthcare (13 results)
- Operational Accounting (11 results)
- Revenue (10 results)
- Financial Accounting (9 results)
- American Oriental Bioengineering Inc. (9 results)
- Investment (9 results)
- Beijing Med-Pharm Corp. (8 results)
- Mergers & Acquisitions (7 results)
- Pharmaceutical Company (7 results)
- NeoStem Inc. (7 results)
- Pfizer Inc. (6 results)
- Net Income (6 results)
- Business Operations (6 results)
- GAAP (5 results)
- Eli Lilly & Co. (5 results)
- Corporate Law (5 results)
- Acquisition (4 results)
- Charles River Laboratories International Inc. (4 results)
- Drug (4 results)
- China-Biotics Inc. (4 results)
- Sales Strategy (3 results)
- Sales (3 results)
- GlaxoSmithKline Plc. (3 results)
- Johnson & Johnson (3 results)
- Manufacturing (3 results)
- Investor (3 results)
Premier Vendor Content Whitepapers, webcasts & resources from our Power Center Sponsors
